Provenance Record

Excellent, carefully-hedged clinical News piece (800 words) that foregrounds the mixed RISE UP result (hemoglobin endpoint met, pain-crisis co-primary missed) and the accelerated-approval pathway, with model Rule-9 stat attribution.

All 4 snapshots read from disk (HTTP 200). source-2 (November 2025 topline release) carries — verbatim — every exact statistic: 40.6% vs 2.9% hemoglobin response (≥1.0 g/dL, Week 24-52), p<0.0001, the 7.69 vs 0.26 g/L hemoglobin change, the -16.03 vs 0.88 µmol/L indirect-bilirubin change, the 2.62 vs 3.05 annualized pain-crisis rate with p=0.1213, and the 'consistent with … prior mitapivat sickle cell disease trials' safety line. source-0 (May 12 sNDA release) confirms the 207-patient 2:1 (138/69) design, the 'oral mitapivat (100 mg) twice daily' dosing, and the PK-activator description. source-3 (BioSpace) confirms the ~159-patient confirmatory trial (age 12+), the 'transfusion free from Week 4 through Week 52' endpoint, the Q3-2026 acceptance / 60-day review, the 'first PK activator approved in the U.S.' claim, and the Sarah Gheuens quote. source-1 (EHA release) confirms the two primary endpoints, the Stockholm June 11-14 congress, the 'one of only six selected' plenary detail, and the June 13 9:00 a.m. ET call.

Exemplary Rule-9 discipline: every exact percentage and p-value is cited to the November 2025 topline release that actually contains it, NOT the May sNDA release that omits them. Every quote is verbatim and correctly attributed; minor renderings ('(100 mg) twice daily' → 'at 100 mg twice daily', 'transfusion free' → 'transfusion-free') are faithful. The internal cross-reference to the April Editas CRISPR sickle-cell article was verified to exist.

High-quality, fully-verified clinical submission with model primary-source statistic attribution. APPROVE.